TARA Protara Therapeutics, Inc.

NASDAQ
$3.97

Protara Therapeutics, Inc. (TARA) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.36 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.8% since its last earnings release on August 11, 2026.

Protara Therapeutics Missed Consensus Estimates
Tuesday, August 11, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · After Close
Earnings Whisper
-
vs ($0.36)
Rev est $7M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.92

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Protara Therapeutics, Inc.

Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. Protara Therapeutics Inc., formerly known as ArTara Therapeutics, is based in NEW YORK, United States.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow